Partner Headlines - BMY

  1. Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of ...

    Benzinga
  2. UPDATE: USDA Approves Supplimental Biologics License

    Benzinga
  3. USDA Accepts Supplemental Biologics License Application for Yervoy ...

    Benzinga
  4. Bristol Myers Reports Data Supporting Clinical Development Of ...

    Benzinga
  5. Biotech Pharmacyclics Spikes On Buyout Rumors

    IBD
  6. Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug

    Benzinga
  7. Lannett Joins Big-Game Hunt For Drugmaker Acquisitions

    IBD
  8. Bristol-Myers goes for the gut

    IBD
  9. Drugmaker Mylan Takes Part In Pharma Feeding Frenzy

    IBD
  10. Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals ...

    GuruFocus
  11. Pharma M&A: Bristol-Myers, Valeant Make Deals

    IBD
  12. Morning Market Gainers

    Benzinga
  13. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  14. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  15. Strong Dollar Weakens Views

    IBD
  16. Drugmakers Warn On Dollar

    IBD
  17. Strong Dollar Pins U.S. Corporate Earnings Outlook

    IBD
  18. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  19. Strong Dollar Means Flabby Outlook For Some Overseas

    IBD
  20. Bristol, Pfizer, Novartis Forecasts Face FX Pressures

    IBD
  21. Tuesday Morning Movers: Microsoft, Procter & Gamble Tumble Following ...

    Benzinga
  22. UPDATE: Bristol-Meyers Squibb Posts Upbeat Q4 Results, Issues ...

    Benzinga
  23. Earnings Scheduled For January 27, 2015

    Benzinga
  24. Pharmaceuticals Sector To See High Voltage Action in 2015

    GuruFocus
  25. 3 High-Flying Health Care Stock IPOs To Watch In 2015

    IBD
  26. BRISTOL-MYERS SQUIBB

    IBD
  27. Bristol-Myers Squibb Names Caforio CEO, Andreotti To Become Chairman

    Benzinga
  28. Feeling Good With This Med Company

    GuruFocus
  29. 10 Biotech Stories You Might've Missed This Week

    Benzinga
  30. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  31. Celgene Outlook Is Upbeat

    IBD
  32. Celgene, Bristol-Myers Cancer Drug News Lifts Stocks

    IBD
  33. Bristol-Myers Hits 14-Year High On Cancer Drug Trial

    IBD
  34. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  35. Morning Market Gainers

    Benzinga
  36. Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2 ...

    Benzinga
  37. What Investors Should Expect From Portola Pharmaceutical's Upcoming ...

    Benzinga
  38. Jim Cramer Advises His Viewers On Wynn Resorts And Second Sight ...

    Benzinga
  39. Bristol-Myers Squibb and California Institute for Biomedical ...

    Benzinga
  40. 5 Biotech Stocks With Big News Due In January

    IBD
  41. FDA's OKs may prescribe hits

    IBD
  42. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  43. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  44. Celgene drug could gain share

    IBD
  45. Celgene's Abraxane Succeeds In Early Breast Cancer

    IBD
  46. Merck's Keytruda Might Treat Virulent Breast Cancer

    IBD
  47. US Stock Futures Edge Lower Ahead Of Federal Budget

    Benzinga
  48. T Rowe Price's Top Stakes for the Third Quarter

    GuruFocus
  49. I think Zimmer Will Outperform S&P 500 Performance

    GuruFocus
  50. Avanir Stock Jumps On $3.5 Billion Otsuka Buyout

    IBD
  51. A Buy Recommendation From Absolute Valuation Model to Bristol-Myers ...

    GuruFocus
  52. Screening Pharma Stocks Amid Turnaround

    YCharts
  53. Incyte Building Blockbuster Drug One Disease At A Time

    IBD
  54. Blackhill Bets Almost Half of Portfolio on Williams-Sonoma

    GuruFocus
  55. Merck Down On Hepatitis C Data; Gilead Rises

    IBD
  56. A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio

    GuruFocus
  57. Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb ...

    Benzinga
  58. Lung cancer drug promising

    IBD
  59. Bristol-Myers Lung-Cancer Drug Boosts Survival

    IBD
  60. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line ...

    Benzinga
  61. Eliquis revives Bristol-Myers

    IBD
  62. Bristol-Myers Beats Q3 Views As Eliquis Revives

    IBD
  63. Stocks Flat In Mixed Volume; Amazon.com Weighs On Techs

    IBD
  64. UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates

    Benzinga
  65. Stock Futures Aim For Flat Open; Amazon.com Crumples On Q3 Miss

    IBD
  66. #PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets

    Benzinga
  67. Earnings Scheduled For October 24, 2014

    Benzinga
  68. Must Watch Stocks for Today

    Benzinga
  69. Stocks Rebound; Amazon.com Slides After Hours

    IBD
  70. Drug ETFs Attractive Buys On Pullback

    Benzinga
  71. Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, ...

    GuruFocus
  72. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  73. Apple Leads the Charge as Earnings Season Heats Up

    FoxBusiness
  74. The Six Types of Winning Stocks

    GuruFocus
  75. Markets Debut Week On Negative Note; S&P 500 Falls Through Key ...

    Benzinga
  76. Merck to release hep C data

    IBD
  77. Merck, Bristol, Arrowhead Prep Hepatitis Studies

    IBD
  78. Salix, Actavis Among Big Cap Pharmas In Merger Mambo

    IBD
  79. Bristol-Myers pulls FDA filing

    IBD
  80. Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo

    IBD
  81. Bristol-Myers Squibb Statement About Asunaprevir In The US, WIthdraws ...

    Benzinga
  82. 2 Mutual Funds Holding Hospital Stocks

    Benzinga
  83. NeurOp Receives Milestone Payment As Bristol-Myers Squibb Nominates ...

    Benzinga
  84. Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly ...

    Benzinga
  85. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  86. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD
  87. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. ...

    Benzinga
  88. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD
  89. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  90. Booming Biotech Market Benefits REIT BioMed Realty

    IBD
  91. Bristol-Myers: Absolute Valuation Model versus Relative Valuation ...

    GuruFocus
  92. Bristol-Myers Drug Gets OK

    IBD
  93. Markets Little Changed In Low Volume And Slow News Ahead Of Long ...

    Benzinga
  94. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers ...

    Benzinga
  95. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD
  96. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga
  97. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD
  98. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  99. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  100. Drugmaker AstraZeneca Returns To Growth

    IBD
Trading Center